BMS patent cliffs:-Biopharma companies are constantly combating...

BMS patent cliffs:-

Biopharma companies are constantly combating patent expirations. But three large drug makers in particular will be the most negatively impacted from expected exclusivity losses by 2030.
Among 19 large U.S. and European biopharma companies, Bristol Myers Squibb, Amgen and Pfizer will face two major issues. All three companies will have a large portion of their 2025 revenues exposed to generic or biosimilar competition, and they will also see those revenues erode quickly, an SVB Leerink team led by analyst Geoffrey Porges.
BMS, Amgen and Pfizer will likely see copycats eat away 47%, 29% and 28% of their respective anticipated 2025 total revenues by 2030.

BMS itself has outlined around $12 billion to $14 billion related to exclusivity losses between 2020 and 2025 led by Revlimid, the patent for which expires in 2022. To fill the gap, the company plans to have several new products that could collectively deliver over $25 billion non-risk-adjusted revenue in 2029. These include anemia drug Reblozyl, heart drug mavacamten, TYK2 inhibitor deucravacitinib for inflammatory diseases and LAG-3 immuno-oncology agent relatlimab, among others.